Back to Search Results
Image Place holder

Heiko Enderling, PhD

Program: Integrated Mathematical Oncology

View Lab Page

Google Scholar Profile

Overview


Associations

    • Integrated Mathematical Oncology
    • Radiation Oncology
    • Genitourinary Oncology
    • Cancer Biology and Evolution Program
    • Evolutionary Therapy

Education & Training

Graduate:

  • University of Dundee, PhD - Mathematical Biology

Fellowship:

  • University of Dundee, Postdoctoral Researcher - Mathematics, Surgery, Molecular Oncology
  • Tufts University School of Medicine, Postdoctoral Fellow
Research

Dr. Enderling's research interests are focused on developing clinically and experimentally motivated and quantitative models of cell-cell interactions within a tumor as well as at the tumor-host interface. In particular, the work in his laboratory focuses on the role of cancer stem cells in tumor progression and treatment response, with the ultimate goal to improve patient-specific treatment design.

Publications

  • Harshe I, Enderling H, Brady-Nicholls R. Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?. Cancers (Basel). 2023 Feb.15(5). Pubmedid: 36900161. Pmcid: PMC10000065.
  • Shyntar A, Patel A, Rhodes M, Enderling H, Hillen T. The Tumor Invasion Paradox in Cancer Stem Cell-Driven Solid Tumors. Bull Math Biol. 2022 Oct.84(12):139. Pubmedid: 36301402. Pmcid: PMC9613767.
  • Brady-Nicholls R, Enderling H. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358738. Pmcid: PMC9657943.
  • Enderling H. Mathematical oncology: A new frontier in cancer biology and clinical decision making: Comment on "Improving cancer treatments via dynamical biophysical models" by M. Kuznetsov, J. Clairambault & V. Volpert. Phys Life Rev. 2022 Mar.40:60-62. Pubmedid: 34857476.
  • Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Author Correction: Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2022 Mar.12(1):4441. Pubmedid: 35292722. Pmcid: PMC8924186.
  • Bekker RA, Kim S, Pilon-Thomas S, Enderling H. Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia. 2022 Jun.28:100796. Pubmedid: 35447601. Pmcid: PMC9043662.
  • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
  • Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35793871. Pmcid: PMC9260835.
  • Ghaffari Laleh N, Loeffler CML, Grajek J, Staňková K, Pearson AT, Muti HS, Trautwein C, Enderling H, Poleszczuk J, Kather JN. Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol. 2022 Feb.18(2):e1009822. Pubmedid: 35120124. Pmcid: PMC8903251.
  • Kirtane KS, Zahid MU, Enderling H, Harrison LB. Reimagining Cancer Staging in the Era of Evolutionary Oncology. J Natl Compr Canc Ne. 2022 Dec.20(12):1370-1372. Pubmedid: 36509079.
  • Buchsbaum JC, Jaffray DA, Ba D, Borkon LL, Chalk C, Chung C, Coleman MA, Coleman CN, Diehn M, Droegemeier KK, Enderling H, Espey MG, Greenspan EJ, Hartshorn CM, Hoang T, Hsiao HT, Keppel C, Moore NW, Prior F, Stahlberg EA, Tourassi G, Willcox KE. Predictive Radiation Oncology - A New NCI-DOE Scientific Space and Community. Radiat Res. 2022 Apr.197(4):434-445. Pubmedid: 35090025. Pmcid: PMC9058979.
  • Glazar DJ, Johnson M, Farinhas J, Steuer CE, Saba NF, Bonomi M, Chung CH, Enderling H. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral Oncol. 2022 Apr.127:105787. Pubmedid: 35248922.
  • Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. Neoplasia. 2021 Sep.23(9):851-858. Pubmedid: 34298234. Pmcid: PMC8322456.
  • Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2021 Oct.11(1):20219. Pubmedid: 34642366. Pmcid: PMC8511136.
  • Zahid MU, Mohsin N, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model. Int J Radiat Oncol Biol Phys. 2021 Nov.111(3):693-704. Pubmedid: 34102299. Pmcid: PMC8463501.
  • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
  • Pasetto S, Enderling H, Gatenby RA, Brady-Nicholls R. Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer. Bull Math Biol. 2021 Nov.84(1):2. Pubmedid: 34797430. Pmcid: PMC8604892.
  • Zahid MU, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization. J Pers Med. 2021 Nov.11(11). Pubmedid: 34834476. Pmcid: PMC8622616.
  • Pasetto S, Gatenby RA, Enderling H. Bayesian Framework to Augment Tumor Board Decision Making. JCO Clin Cancer Inform. 2021 May.5:508-517. Pubmedid: 33974446. Pmcid: PMC8240793.
  • Tomaszewski MR, Dominguez-Viqueira W, Ortiz A, Shi Y, Costello JR, Enderling H, Rosenberg SA, Gillies RJ. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy. Nmr Biomed. 2021 Mar.34(3):e4454. Pubmedid: 33325086.
  • Liu J, Hormuth DA, Davis T, Yang J, McKenna MT, Jarrett AM, Enderling H, Brock A, Yankeelov TE. A time-resolved experimental-mathematical model for predicting the response of glioma cells to single-dose radiation therapy. Integr Biol (Camb). 2021 Jul.13(7):167-183. Pubmedid: 34060613. Pmcid: PMC8271006.
  • Walker SA, Pham A, Nizzero S, Kim M, Riter B, Bletz J, Judge S, Phillips B, Noble D, Murray D, Wetzel E, Samson S, McMahon M, Flink C, Couch J, Tomlin C, Swanson K, Anderson ARA, Odde D, Shen H, Hughes S, Zahir N, Enderling H, Wolfram J. Education and Outreach in Physical Sciences in Oncology. Trends Cancer. 2021 Jan.7(1):3-9. Pubmedid: 33168416. Pmcid: PMC7895467.
  • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
  • Enderling H. Re: Numerical simulation of normal and cancer cells' populations with fractional derivative under radiotherapy. Comput Methods Programs Biomed. 2020 May.188:105417. Pubmedid: 32131982.
  • Glazar DJ, Grass GD, Arrington JA, Forsyth PA, Raghunand N, Yu HM, Sahebjam S, Enderling H. Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma. J Clin Med. 2020 Jun.9(7). Pubmedid: 32605050. Pmcid: PMC7409184.
  • Enderling H, Altrock PM, Andor N, Basanta D, Brown JS, Gatenby RA, Marusyk A, Rejniak KA, Silva A, Anderson ARA. High School Internship Program in Integrated Mathematical Oncology (HIP IMO): Five-Year Experience at Moffitt Cancer Center. Bull Math Biol. 2020 Jul.82(7):91. Pubmedid: 32648152.
  • Lewin T, Byrne H, Maini PK, Caudell JJ, Moros EG, Enderling H. The importance of dead material within a tumour on the dynamics in response to radiotherapy. Phys Med Biol. 2020 Jan.65(1):015007. Pubmedid: 31593931.
  • Enderling H, Wolkenhauer O. Are all models wrong?. Comput Syst Oncol. 2020 Dec.1(1). Pubmedid: 33585835. Pmcid: PMC7880041.
  • Aherne NJ, Dhawan A, Scott JG, Enderling H. Mathematical oncology and it's application in non melanoma skin cancer - A primer for radiation oncology professionals. Oral Oncol. 2020 Apr.103:104473. Pubmedid: 32109841.
  • Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nat Commun. 2020 Apr.11(1):1750. Pubmedid: 32273504. Pmcid: PMC7145869.
  • Heidbuechel JPW, Abate-Daga D, Engeland CE, Enderling H. Mathematical Modeling of Oncolytic Virotherapy. Methods Mol Biol. 2019 Sep.2058:307-320. Pubmedid: 31486048.
  • Sunassee ED, Tan D, Ji N, Brady R, Moros EG, Caudell JJ, Yartsev S, Enderling H. Proliferation saturation index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses. Int J Radiat Biol. 2019 Oct.95(10):1421-1426. Pubmedid: 30831050. Pmcid: PMC7081883.
  • Brady R, Enderling H. Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to. Bull Math Biol. 2019 Oct.81(10):3722-3731. Pubmedid: 31338741. Pmcid: PMC6764933.
  • Rockne RC, Hawkins-Daarud A, Swanson KR, Sluka JP, Glazier JA, Macklin P, Hormuth D, Jarrett AM, Lima EABDF, Oden J, Biros G, Yankeelov TE, Curtius K, Bakir IA, Wodarz D, Komarova N, Aparicio L, Bordyuh M, Rabadan R, Finley S, Enderling H, Caudell JJ, Moros EG, Anderson ARA, Gatenby R, Kaznatcheev A, Jeavons P, Krishnan N, Pelesko J, Wadhwa RR, Yoon N, Nichol D, Marusyk A, Hinczewski M, Scott JG. The 2019 mathematical oncology roadmap. Phys Biol. 2019 Jun.16(4):041005. Pubmedid: 30991381. Pmcid: PMC6655440.
  • Ferrall-Fairbanks MC, Glazar DJ, Brady RJ, Kimmel GJ, Zahid MU, Altrock PM, Enderling H. Re: Simulation analysis for tumor radiotherapy based on three-component mathematical models. J Appl Clin Med Phys. 2019 Jul.20(7):204-205. Pubmedid: 31145529. Pmcid: PMC6612696.
  • Enderling H, Alfonso JCL, Moros E, Caudell JJ, Harrison LB. Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy. Trends Cancer. 2019 Aug.5(8):467-474. Pubmedid: 31421904.
  • Schacht C, Meade A, Banks HT, Enderling H, Abate-Daga D. Estimation of probability distributions of parameters using aggregate population data: analysis of a CAR T-cell cancer model. Math Biosci Eng. 2019 Aug.16(6):7299-7326. Pubmedid: 31698614.
  • Walker R, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Coppola D, Enderling H. Personalizing Gastric Cancer Screening With Predictive Modeling of Disease Progression Biomarkers. Appl Immunohistochem Mol Morphol. 2019 Apr.27(4):270-277. Pubmedid: 29084052.
  • López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H. Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clin Cancer Inform. 2019 Apr.3:1-16. Pubmedid: 30964698. Pmcid: PMC6661069.
  • Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H. Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. Front Phys. 2019 Apr.7. Pubmedid: 31123672. Pmcid: PMC6529192.
  • Poleszczuk J, Enderling H. The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. Int J Mol Sci. 2018 Oct.19(11). Pubmedid: 30380596. Pmcid: PMC6275030.
  • Poleszczuk J, Walker R, Moros EG, Latifi K, Caudell JJ, Enderling H. Predicting Patient-Specific Radiotherapy Protocols Based on Mathematical Model Choice for Proliferation Saturation Index. Bull Math Biol. 2018 May.80(5):1195-1206. Pubmedid: 28681150.
  • Lewin TD, Maini PK, Moros EG, Enderling H, Byrne HM. The Evolution of Tumour Composition During Fractionated Radiotherapy: Implications for Outcome. Bull Math Biol. 2018 May.80(5):1207-1235. Pubmedid: 29488054.
  • Walker R, Poleszczuk J, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Enderling H, Coppola D. Toward early detection of Helicobacter pylori-associated gastric cancer. Gastric Cancer. 2018 Mar.21(2):196-203. Pubmedid: 28725964. Pmcid: PMC7810132.
  • Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep. 2018 Jun.8(1):9474. Pubmedid: 29930290. Pmcid: PMC6013469.
  • López Alfonso JC, Parsai S, Joshi N, Godley A, Shah C, Koyfman SA, Caudell JJ, Fuller CD, Enderling H, Scott JG. Temporally feathered intensity-modulated radiation therapy: A planning technique to reduce normal tissue toxicity. Med Phys. 2018 Jul.45(7):3466-3474. Pubmedid: 29786861. Pmcid: PMC6041138.
  • Forouzannia F, Enderling H, Kohandel M. Mathematical Modeling of the Effects of Tumor Heterogeneity on the Efficiency of Radiation Treatment Schedule. Bull Math Biol. 2018 Feb.80(2):283-293. Pubmedid: 29218592.
  • Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix CC, Welsh JW, Krishnan S, Yothers G, Brown JM, Knox SJ, Bristow RG, Spellman PT, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng FY, Galbraith SM, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, FitzGerald TJ, Laurie F, Marshall DT, Raben D, Constine LS, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 Aug.24(15):3500-3509. Pubmedid: 29661779.
  • Howard R, Al Diffalha S, Pimiento J, Mejia J, Enderling H, Giuliano A, Coppola D. CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression. Anticancer Res. 2018 Aug.38(8):4443-4448. Pubmedid: 30061208. Pmcid: PMC7771274.
  • Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H. Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. Converg Sci Phys Oncol. 2017 Sep.3(3). Pubmedid: 29774168. Pmcid: PMC5949881.
  • Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017 May.18(5):e266-e273. Pubmedid: 28456586. Pmcid: PMC7771279.
  • Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017 Jun.19(1):75. Pubmedid: 28666457. Pmcid: PMC5493088.
  • Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 Aug.39(8):1609-1620. Pubmedid: 28464542. Pmcid: PMC5511768.
  • Sasi SP, Yan X, Zuriaga-Herrero M, Gee H, Lee J, Mehrzad R, Song J, Onufrak J, Morgan J, Enderling H, Walsh K, Kishore R, Goukassian DA. Different Sequences of Fractionated Low-Dose Proton and Single Iron-Radiation-Induced Divergent Biological Responses in the Heart. Radiat Res. 2017 Aug.188(2):191-203. Pubmedid: 28613990. Pmcid: PMC6555403.
  • Santiago DN, Heidbuechel JPW, Kandell WM, Walker R, Djeu J, Engeland CE, Abate-Daga D, Enderling H. Fighting Cancer with Mathematics and Viruses. Viruses. 2017 Aug.9(9). Pubmedid: 28832539. Pmcid: PMC5618005.
  • Poleszczuk J, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, Djeu JY, Finkelstein SE, Enderling H. Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions. Cancer Res. 2016 Mar.76(5):1009-1018. Pubmedid: 26833128.
  • Poleszczuk J, Enderling H. Cancer Stem Cell Plasticity as Tumor Growth Promoter and Catalyst of Population Collapse. Stem Cells Int. 2016 Feb.2016:3923527. Pubmedid: 26858759. Pmcid: PMC4686719.
  • Sasi SP, Park D, Muralidharan S, Wage J, Kiladjian A, Onufrak J, Enderling H, Yan X, Goukassian DA. Corrigendum to "Particle Radiation-Induced Nontargeted Effects in Bone-Marrow-Derived Endothelial Progenitor Cells". Stem Cells Int. 2016 Feb.2016:7958361. Pubmedid: 26880990. Pmcid: PMC4736558.
  • Walker R, Enderling H. From concept to clinic: Mathematically informed immunotherapy. Curr Prob Cancer. 2016 Dec.40(1):68-83. Pubmedid: 26645497.
  • Perni S, Mohamed AS, Scott J, Enderling H, Garden AS, Gunn GB, Rosenthal DI, Fuller CD. CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. Oral Oncol. 2016 Dec.63:16-22. Pubmedid: 27938995. Pmcid: PMC5157841.
  • Poleszczuk JT, Johnstone PA, Enderling H. Stratifying prostate cancer patients by relative lymph node involvement: population- and modeling-based study. Cancer Med. 2016 Aug.5(8):1850-1855. Pubmedid: 27227813. Pmcid: PMC4884636.
  • Poleszczuk J, Macklin P, Enderling H. Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth. Methods Mol Biol. 2016 Apr.1516:335-346. Pubmedid: 27044046. Pmcid: PMC6587968.
  • Sasi SP, Song J, Park D, Enderling H, McDonald JT, Gee H, Garrity B, Shtifman A, Yan X, Walsh K, Natarajan M, Kishore R, Goukassian DA. TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J Biol Chem. 2015 Nov.290(45):27014. Pubmedid: 26546693. Pmcid: PMC4646378.
  • Poleszczuk J, Hahnfeldt P, Enderling H. Evolution and phenotypic selection of cancer stem cells. PLoS Comput Biol. 2015 Mar.11(3):e1004025. Pubmedid: 25742563. Pmcid: PMC4351192.
  • Poleszczuk J, Hahnfeldt P, Enderling H. Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS One. 2015 Mar.10(3):e0120007. Pubmedid: 25785600. Pmcid: PMC4364928.
  • Johnstone PA, Enderling H. Mathematical Modeling of Acupuncture as Cancer Symptom Therapy: First Steps. J Acupunct Meridian Stud. 2015 Jun.8(3):113-114. Pubmedid: 26100063.
  • Prokopiou S, Moros EG, Poleszczuk J, Caudell J, Torres-Roca JF, Latifi K, Lee JK, Myerson R, Harrison LB, Enderling H. A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. Radiat Oncol. 2015 Jul.10:159. Pubmedid: 26227259. Pmcid: PMC4521490.
  • Enderling H. Cancer stem cells: small subpopulation or evolving fraction?. Integr Biol (Camb). 2015 Jan.7(1):14-23. Pubmedid: 25359461.
  • Yan X, Sasi SP, Gee H, Lee J, Yang Y, Mehrzad R, Onufrak J, Song J, Enderling H, Agarwal A, Rahimi L, Morgan J, Wilson PF, Carrozza J, Walsh K, Kishore R, Goukassian DA. Correction: Cardiovascular Risks Associated with Low Dose Ionizing Particle Radiation. PLoS One. 2015.10(11):e0142764. Pubmedid: 26544605. Pmcid: PMC4636225.
  • Sasi SP, Bae S, Song J, Perepletchikov A, Schneider D, Carrozza J, Yan X, Kishore R, Enderling H, Goukassian DA. Correction: Therapeutic Non-Toxic Doses of TNF Induce Significant Regression in TNFR2-p75 Knockdown Lewis Lung Carcinoma Tumor Implants. PLoS One. 2015.10(11):e0144213. Pubmedid: 26619137. Pmcid: PMC4664239.
  • Yan X, Sasi SP, Gee H, Lee J, Yang Y, Mehrzad R, Onufrak J, Song J, Enderling H, Agarwal A, Rahimi L, Morgan J, Wilson PF, Carrozza J, Walsh K, Kishore R, Goukassian DA. Cardiovascular risks associated with low dose ionizing particle radiation. PLoS One. 2014 Oct.9(10):e110269. Pubmedid: 25337914. Pmcid: PMC4206415.
  • P Sasi S, Song J, Park D, Enderling H, McDonald JT, Gee H, Garrity B, Shtifman A, Yan X, Walsh K, Natarajan M, Kishore R, Goukassian DA. TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J Biol Chem. 2014 May.289(20):14178-14193. Pubmedid: 24711449. Pmcid: PMC4022885.
  • Sasi SP, Song J, Enderling H, Yan X, Goukassian DA. TNF-α and IL-1α but not MCP-1 and Rantes increase significantly the formation of p-H2AX foci in naive BM-derived TNFR1/p55KO EPCs. J Radiat Res. 2014 Mar.55 Suppl 1:i122-i123. Pmcid: PMC3941533.
  • Sasi SP, Bae S, Song J, Perepletchikov A, Schneider D, Carrozza J, Yan X, Kishore R, Enderling H, Goukassian DA. Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants. PLoS One. 2014 Mar.9(3):e92373. Pubmedid: 24664144. Pmcid: PMC3963887.
  • Weekes SL, Barker B, Bober S, Cisneros K, Cline J, Thompson A, Hlatky L, Hahnfeldt P, Enderling H. A multicompartment mathematical model of cancer stem cell-driven tumor growth dynamics. Bull Math Biol. 2014 Jul.76(7):1762-1782. Pubmedid: 24840956. Pmcid: PMC4140966.
  • Poleszczuk J, Enderling H. A High-Performance Cellular Automaton Model of Tumor Growth with Dynamically Growing Domains. Appl Math (Irvine). 2014 Jan.5(1):144-152. Pubmedid: 25346862. Pmcid: PMC4208695.
  • Enderling H, Chaplain MA. Mathematical modeling of tumor growth and treatment. Curr Pharm Des. 2014 Dec.20(30):4934-4940. Pubmedid: 24283955.
  • McGuire MF, Enderling H, Wallace DI, Batra JS, Jordan M, Kumar S, Panetta JC, Pasquier E. Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. Cancer Res. 2013 Oct.73(20):6111-6117. Pubmedid: 23955390. Pmcid: PMC4040396.
  • Gao X, McDonald JT, Hlatky L, Enderling H. Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Res. 2013 Mar.73(5):1481-1490. Pubmedid: 23269274. Pmcid: PMC3594421.
  • Hillen T, Enderling H, Hahnfeldt P. The tumor growth paradox and immune system-mediated selection for cancer stem cells. Bull Math Biol. 2013 Jan.75(1):161-184. Pubmedid: 23196354.
  • Enderling H. Cancer stem cells and tumor dormancy. Adv Exp Med Biol. 2013 Apr.734:55-71. Pubmedid: 23143975.
  • Enderling H, Hlatky L, Hahnfeldt P. Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features. Front Oncol. 2013.3:76. Pubmedid: 23596563. Pmcid: PMC3625721.
  • Enderling H, Rejniak KA. Simulating cancer: computational models in oncology. Front Oncol. 2013.3:233. Pubmedid: 24062986. Pmcid: PMC3772565.
  • Enderling H. Unveiling stem cell kinetics: prime time for integrating experimental and computational models. Front Oncol. 2013.3:291. Pubmedid: 24350056. Pmcid: PMC3842622.
  • Sasi SP, Yan X, Enderling H, Park D, Gilbert HY, Curry C, Coleman C, Hlatky L, Qin G, Kishore R, Goukassian DA. Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene. 2012 Sep.31(37):4117-4127. Pubmedid: 22158049.
  • Enderling H, Hahnfeldt P, Hlatky L, Almog N. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. Cancer Res. 2012 May.72(9):2172-2175. Pubmedid: 22414579. Pmcid: PMC3374524.
  • Enderling H, Hlatky L, Hahnfeldt P. The promoting role of a tumour-secreted chemorepellent in self-metastatic tumour progression. Math Med Biol. 2012 Mar.29(1):21-29. Pubmedid: 20929852.
  • Enderling H, Hlatky L, Hahnfeldt P. Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor Biol Med Model. 2012 Jul.9:31. Pubmedid: 22838395. Pmcid: PMC3499182.
  • Morton CI, Hlatky L, Hahnfeldt P, Enderling H. Non-stem cancer cell kinetics modulate solid tumor progression. Theor Biol Med Model. 2011 Dec.8:48. Pubmedid: 22208390. Pmcid: PMC3285090.
  • Enderling H, Hahnfeldt P. Cancer stem cells in solid tumors: is 'evading apoptosis' a hallmark of cancer?. Prog Biophys Mol Biol. 2011 Aug.106(2):391-399. Pubmedid: 21473880.
  • Tang J, Enderling H, Becker-Weimann S, Pham C, Polyzos A, Chen CY, Costes SV. Phenotypic transition maps of 3D breast acini obtained by imaging-guided agent-based modeling. Integr Biol (Camb). 2011 Apr.3(4):408-421. Pubmedid: 21373705. Pmcid: PMC4009383.
  • Enderling H, Chaplain MA, Hahnfeldt P. Quantitative modeling of tumor dynamics and radiotherapy. Acta Biotheor. 2010 Dec.58(4):341-353. Pubmedid: 20658170.
  • Enderling H, Hlatky L, Hahnfeldt P. Tumor morphological evolution: directed migration and gain and loss of the self-metastatic phenotype. Biol Direct. 2010 Apr.5:23. Pubmedid: 20406441. Pmcid: PMC2868833.
  • Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res. 2009 Nov.69(22):8814-8821. Pubmedid: 19887613.
  • Enderling H, Hlatky L, Hahnfeldt P. Migration rules: tumours are conglomerates of self-metastases. Br J Cancer. 2009 Jun.100(12):1917-1925. Pubmedid: 19455139. Pmcid: PMC2714240.
  • Enderling H, Alexander NR, Clark ES, Branch KM, Estrada L, Crooke C, JourquinJ, Lobdell N, Zaman MH, Guelcher SA, Anderson AR, Weaver AM. Dependence of invadopodia function on collagen fiber spacing and cross-linking: computational modeling and experimental evidence. Biophys J. 2008 Sep.95(5):2203-2218. Pubmedid: 18515372. Pmcid: PMC2517013.
  • Enderling H, Chaplain M, Anderson A, Vaidya J. A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol. 2007 May.246(2):245-259. Pubmedid: 17289081.
  • Enderling H, Anderson AR, Chaplain MA, Rowe GW. Visualisation of the numerical solution of partial differential equation systems in three space dimensions and its importance for mathematical models in biology. Math Biosci Eng. 2006 Oct.3(4):571-582. Pubmedid: 20361833.
  • Enderling H, Anderson A, Chaplain M, Munro A, Vaidya J. Mathematical modelling of radiotherapy strategies for early breast cancer. J Theor Biol. 2006 Jul.241(1):158-171. Pubmedid: 16386275.

Grants

  • Title: Adaptive Radiation Fractionation in HPV+ Oropharyngeal Cancer
    Sponsor: Moffitt Cancer Center
    PI: Enderling, H., CO-PI: Caudell, J., CO-PI: Torres-Roca, J.
  • Title: Ventilator IP (20MA021)
    Sponsor: Moffitt Cancer Center
    PI: Enderling, H.
  • Title: Developing Mathematical Model Driven Optimized Recurrent Glioblastoma Therapies
    Sponsor: Nat Institutes of Health
    PI (Contact): Enderling, H., PI (MPI): Yu, M.
  • Title: Innovative Mathematical Oncology Approaches to Identify Patient-Specific Biomarkers to Personalize Radiation Therapy for Breast Cancer Patients
    Sponsor: Jayne Koskinas & Ted Giovanis Foundation for Health Policy
    PI: Enderling, H.
  • Title: Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
    Sponsor: Nat Institutes of Health
    PI (Contact): Enderling, H., PI (MPI): Pilon-Thomas, S.